- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
- Interventions
- Not listed
- Lead sponsor
- Sanguine Biosciences
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 17,667 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 61
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Myasthenia Gravis, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Efgartigimod
- Biological
- Lead sponsor
- argenx
- Industry
- Eligibility
- Female only
- Enrollment
- 279 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2033
- U.S. locations
- 1
- States / cities
- Morgantown, West Virginia
- Conditions
- CIDP
- Interventions
- IVIg
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Interventions
- Empasiprubart IV, Placebo IV
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • Rancho Mirage, California • Colorado Springs, Colorado + 8 more
- Conditions
- B-cell Mediated Autoimmune Disorders
- Interventions
- Azercabtagene zapreleucel (azer-cel)
- Drug
- Lead sponsor
- TG Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- La Jolla, California • Ann Arbor, Michigan • Omaha, Nebraska + 5 more
- Conditions
- Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
- Interventions
- Not listed
- Lead sponsor
- Global Healthy Living Foundation
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 40,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2025
- U.S. locations
- 1
- States / cities
- Upper Nyack, New York
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Batoclimab
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Ormond Beach, Florida • Nicholasville, Kentucky + 2 more
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- riliprubart, Placebo, IVIg
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 32
- States / cities
- Homewood, Alabama • Scottsdale, Arizona • Los Angeles, California + 27 more
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Non-invasive vagus nerve stimulation (nVNS), Standard of care treatment
- Device · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 5 Years to 21 Years
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, CIDP, CIDP - Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- empasiprubart, IVIg, empasiprubart-placebo, IVIg-placebo
- Biological · Other
- Lead sponsor
- argenx
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Rancho Mirage, California • Colorado Springs, Colorado + 12 more
- Conditions
- Healthy, Primary Immune Thrombocytopenia, Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Interventions
- PF-06755347 intravenous healthy participant, Placebo intravenous healthy participant, PF-06755347 subcutaneous healthy participant, Placebo subcutaneous healthy participant, PF-06755347 subcutaneous ITP
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- CIDP, Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- lipoic acid
- Drug
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Interventions
- Interferon Beta-1a
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 9 more
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
- Interventions
- Rozanolixizumab, Placebo
- Drug · Other
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 7
- States / cities
- Phoenix, Arizona • Los Angeles, California • Tampa, Florida + 4 more
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- NVG-2089
- Drug
- Lead sponsor
- Nuvig Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Denton, Texas
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- H.P. Acthar® Gel
- Drug
- Lead sponsor
- Mamatha Pasnoor, MD
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Los Angeles, California • Kansas City, Kansas + 2 more
- Conditions
- Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis
- Interventions
- Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Laboratory Biomarker Analysis, Melphalan, Peripheral Blood Stem Cell Transplantation, Prednisone, Syngeneic Bone Marrow Transplantation
- Biological · Procedure · Drug + 1 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 71 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2030
- U.S. locations
- 3
- States / cities
- Denver, Colorado • Seattle, Washington
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Imeroprubart, Placebo
- Drug
- Lead sponsor
- Immunovant Sciences GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 33
- States / cities
- Tucson, Arizona • Carlsbad, California • Mission Hills, California + 28 more
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Intravenous Immunoglobulin
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 7
- States / cities
- Johns Creek, Georgia • Chicago, Illinois • Kansas City, Kansas + 4 more
- Conditions
- Chronic Inflammatory Demyelinating Polyradiculoneuropathy
- Interventions
- HYQVIA
- Biological
- Lead sponsor
- Baxalta now part of Shire
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2023
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
- Interventions
- Gamunex-C, Xembify
- Biological
- Lead sponsor
- Grifols Therapeutics LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 7
- States / cities
- Rancho Mirage, California • Coral Springs, Florida • Miami, Florida + 4 more
- Conditions
- CIDP, Immunoglobulin Deficiency, Chronic Inflammatory Demyelinating Polyneuropathy
- Interventions
- Intravenous immune globulin G, Subcutaneous immune globulin G
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Antibody-mediated Rejection, NMO Spectrum Disorder, TTP, CIDP
- Interventions
- Not listed
- Lead sponsor
- Charles M Knudson
- Other
- Eligibility
- 12 Years to 99 Years
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2040
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- Chronic Inflammatory Demyelinating Polyneuropathy, Polyradiculoneuropathy
- Interventions
- IgPro20 (low dose), Placebo, IgPro10, IgPro20 (high dose)
- Biological
- Lead sponsor
- CSL Behring
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 208 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 22
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more